Waist circumference adds to the variance in plasma C-reactive protein levels in elderly patients with metabolic syndrome

被引:28
作者
Dupuy, A. M. [1 ,2 ]
Jaussent, I. [2 ]
Lacroux, A. [3 ]
Durant, R. [4 ]
Cristol, J. P. [1 ]
Delcourt, C. [5 ]
机构
[1] CHU Montpellier, Hop Lapeyronie, Biochem Lab, FR-34295 Montpellier 5, France
[2] Univ Montpellier I, INSERM, E361, Montpellier, France
[3] INSERM, UR024 Epiprev, Inst Rech Dev, Montpellier, France
[4] Ctr Antonin Balmes, Dept Geriatr, Montpellier, France
[5] Univ Victor Segalen Bordeaux 2, INSERM, U593, Bordeaux, France
关键词
adipose tissue; atherosclerosis; C-reactive protein; inflammation; waist circumference;
D O I
10.1159/000103555
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: C- reactive protein ( CRP), a nonspecific marker of the inflammatory status, is associated with cardiovascular disease risk factors and may be an important feature of the metabolic syndrome ( MSX) in middle- aged subjects. Objectives: We assessed the relationship of CRP levels to specific components of MSX and other potential determinants in apparently healthy elderly subjects living in the South of France. Methods: In the framework of the population- based POLA ( Pathologies Oculaires Liees a l'Age) Study, performed in 2,404 subjects aged 60 years or more, we measured the plasma CRP levels. All subjects with known systemic inflammatory diseases, such as chronic bronchitis, cardiovascular disease, and diabetes, and those who were on systemic steroid therapy as well as subjects with CRP levels 1>10 mg/l were excluded from the study, leaving 1,709 subjects for the statistical analyses. MSX was defined according to NCEP ( National Cholesterol Education Program) criteria. Other potential determinants were assessed through interviewer- based questionnaire. Results: We grouped the subjects into three categories based on the 75th and 25th percentiles, corresponding to 3.05 and 0.82, respectively. We compared subjects in the highest quartile, i. e., with CRP >= 3.05 mg/l, with those in the two intermediate quartiles, i. e., with 0.82 < CRP < 3.05, and those in the lowest quartile, i. e., with CRP < 0.82 mg/l according to gender. MSX, which had a prevalence of 31%, was significantly associated with elevated CRP levels. Among MSX components, the strongest positive association with the highest quartile of CRP was with waist circumference in males as well as in females ( age- adjusted odds ratio OR 3.06 and 95% confidence interval Cl 1.82 - 5.14; OR 7.04 and 95% Cl 4.79 - 10.34, respectively). Each component of the MSX, such as abnormal fasting plasma glucose ( OR 2.90, 95% Cl 1.69 - 4.99), triglycerides ( OR 1.96, 95% Cl 1.30 - 2.96), high-density lipoprotein cholesterol ( OR 2.31, 95% Cl 1.61 - 3.30), and blood pressure ( OR 1.66, 95% Cl 1.12 - 2.45), was significantly associated with high CRP values in elderly women only. In men, only current smoking was significantly associated with high CRP levels ( OR 1.52, 95% Cl 1.04 - 2.2). In multivariate analysis, the waist circumference remained significantly associated with high CRP levels, with a graded effect of CRP quartile whatever the gender. In men, current and former smoking remained significantly associated with the CRP levels. In women, the association observed in univariate analysis with fasting glucose or hypertension did not reach statistical significance in the multivariate analysis, while only a weak association could be observed with lipid parameters such as triglycerides and high- density lipoprotein cholesterol. Conclusions: Abdominal adiposity adds to the variance in plasma CRP levels in elderly patients with MSX. This suggests that weight loss or other interventions targeted at adipocyte-related inflammation may represent an important means to prevent subclinical inflammation in the elderly, bearing a high risk of cardiovascular disease. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:329 / 339
页数:11
相关论文
共 64 条
  • [31] Nature's randomised trials
    Hingorani, A
    Humphries, S
    [J]. LANCET, 2005, 366 (9501) : 1906 - 1908
  • [32] Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients
    Hotta, K
    Funahashi, T
    Arita, Y
    Takahashi, M
    Matsuda, M
    Okamoto, Y
    Iwahashi, H
    Kuriyama, H
    Ouchi, N
    Maeda, K
    Nishida, M
    Kihara, S
    Sakai, N
    Nakajima, T
    Hasegawa, K
    Muraguchi, M
    Ohmoto, Y
    Nakamura, T
    Yamashita, S
    Hanafusa, T
    Matsuzawa, Y
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (06) : 1595 - 1599
  • [33] Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort
    Il'yasova, D
    Colbert, LH
    Harris, TB
    Newman, AB
    Bauer, DC
    Satterfield, S
    Kritchevsky, SB
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (10) : 2413 - 2418
  • [34] C-reactive protein: Risk marker or mediator in atherothrombosis?
    Jialal, I
    Devaraj, S
    Venugopal, SK
    [J]. HYPERTENSION, 2004, 44 (01) : 6 - 11
  • [35] Association of markers of systemic inflammation, C reactive protein, serum amyloid A, and fibrinogen, with socioeconomic status
    Jousilahti, P
    Salomaa, V
    Rasi, V
    Vahtera, E
    Palosuo, T
    [J]. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2003, 57 (09) : 730 - 733
  • [36] The metabolic syndrome: Time for a critical appraisal - Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes
    Kahn, R
    Buse, J
    Ferrannini, E
    Stern, M
    [J]. DIABETES CARE, 2005, 28 (09) : 2289 - 2304
  • [37] C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men -: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
    Koenig, W
    Sund, M
    Fröhlich, M
    Fischer, HG
    Löwel, H
    Döring, A
    Hutchinson, WL
    Pepys, MB
    [J]. CIRCULATION, 1999, 99 (02) : 237 - 242
  • [38] C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men
    Laaksonen, DE
    Niskanen, L
    Nyyssönen, K
    Punnonen, K
    Tuomainen, TP
    Valkonen, VP
    Salonen, R
    Salonen, JT
    [J]. DIABETOLOGIA, 2004, 47 (08) : 1403 - 1410
  • [39] Minireview: Adiposity, inflammation, and atherogenesis
    Lyon, CJ
    Law, RE
    Hsueh, WA
    [J]. ENDOCRINOLOGY, 2003, 144 (06) : 2195 - 2200
  • [40] Mendall MA, 1996, BRIT MED J, V312, P1061